Abstracts tagged "Systemic sclerosis"

Abstract Number: 1871 • ACR Convergence 2025
Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis
Elio Carmona¹, Alyssa Rosek², Neha Khanna², Dinesh Khanna³, Amr Sawalha⁴ and Pei-Suen Tsou³, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ³University of Michigan, Ann Arbor, MI, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Our prior research demonstrated that epigenetic modifications are central to the pathogenesis of scleroderma (SSc)1. Using ATAC-seq, we found that chromatin accessibility was significantly…
Abstract Number: 1582 • ACR Convergence 2025
Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Marissa Savoie¹, Monica Harding², John VanBuren², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Luke Evnin⁶, Tracy Frech⁷, Jessica Gordon¹, Faye Hant⁸, Laura Hummers⁹, Dinesh Khanna¹⁰, Kimberly Lakin¹, Dorota Lebiedz-Odrobina², Yiming Luo⁴, Ashima Makol¹¹, Maureen Mayes¹², Zsuzsanna McMahan¹³, Jerry Molitor¹⁴, Duncan Moore¹⁵, Carrie Richardson¹⁶, Nora Sandorfi¹⁷, Ami Shah⁹, Ankoor Shah¹⁸, Brian Skaug¹⁹, Virginia Steen²⁰, Elizabeth Volkmann²¹, Carleigh Zahn¹⁰ and Flavia Castelino²², ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁴Columbia University, New York, NY, ⁵Stanford University, Stanford, CA, ⁶Scleroderma Research Foundation, Brisbane, CA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Medical University of South Carolina, Charleston, SC, ⁹Johns Hopkins Rheumatology, Baltimore, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Mayo Clinic, Rochester, MN, ¹²UT Health Houston Division of Rheumatology, Houston, TX, ¹³UT Health Houston, Houston, TX, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Northwestern Memorial Hospital, Chicago, IL, ¹⁶Northwestern University, Chicago, IL, ¹⁷University of Pennsylvania, Philadelphia, PA, ¹⁸Duke University, Durham, NC, ¹⁹UTHealth Houston Division of Rheumatology, Houston, TX, ²⁰Georgetown University School of Medicine, Washington, DC, ²¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²²Massachusetts General Hospital, Boston, MA
Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…
Abstract Number: 1553 • ACR Convergence 2025
Circulating Monocyte Level Is Associated With Pulmonary Vascular Disease and Right Ventricular Dysfunction in Systemic Sclerosis
Ai Yaku¹, Bong Joon Kim², Hidenori Yaku¹, Carrie Richardson², Michael Cuttica², Ruben Mylvaganam², Vera Rigolin², Matthew Feinstein² and Sanjiv Shah¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago
Background/Purpose: Pulmonary arterial hypertension associated with systemic sclerosis (SSc-PAH) is a life-threatening condition with obliterative pulmonary vascular remodeling, right ventricular (RV) dysfunction, and poor prognosis.…
Abstract Number: 0970 • ACR Convergence 2025
Genomic instability in systemic sclerosis is promoted by metabolic remodelling via a FOXO1-dependent axis
Lamia Khan¹, Junqin Wang², Aishwarya Iyer², Desiree Redmond², Dylan Hennessey², Sandra O'Keefe², Jan Storek³, Charmaine van Eeden², Robert Gniadecki² and Mohammed Osman¹, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³University of Calgary, Calgary, AB, Canada
Background/Purpose: Systemic sclerosis (SSc) is a life-threatening autoimmune disease with limited treatment options, including autologous hematopoietic stem cell transplantation (AHSCT). We recently showed that dermal…
Abstract Number: 0702 • ACR Convergence 2025
Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.
Nicola Farina¹, Silvia Bellando-Randone², hilde Bjørkekjær³, David Launay⁴, Patricia E. Carreira⁵, paolo airò⁶, Serena Guiducci⁷, Dilia Giuggioli⁸, Gabriela Riemekasten⁹, carmen-Pilar Simeón Aznar¹⁰, Christina Bergmann¹¹, Elise Siegert¹², Ivan Castellví¹³, Lesley Ann Saketkoo¹⁴, Jeska de Vries-Bouwstra¹⁵, Dr. Philipp Klemm¹⁶, ulf Müller-Ladner¹⁷, Alexandra Balbir- Gurman¹⁸, Vanessa Smith¹⁹, Florenzo Iannone²⁰, Luca Idolazzi²¹, Christopher Denton²², edoardo rosato²³, Britta Maurer²⁴, Yannick Allanore²⁵, Yoshiya Tanaka²⁶, elisabetta zanatta²⁷, Marie-Elise Truchetet²⁸, Masataka Kuwana²⁹, Mickaël MARTIN³⁰, Alberto Cauli³¹, Kamal Solanki³², Francesco Del Galdo³³, Ana Maria Gheorghiu³⁴, Branimir Anic³⁵, Gábor Kumánovics³⁶, Gonçalo Boleto³⁷, Kristofer Andréasson³⁸, Simona Rednic³⁹, Lorinda Chung⁴⁰, susana Oliveira⁴¹, marius cadar⁴², Francesco Paolo Cantatore⁴³, Carolina de Souza Müller⁴⁴, Vivien Hsu⁴⁵, Yair Levy⁴⁶, Gianluca Moroncini⁴⁷, Jörg Henes⁴⁸, Andra Balanescu⁴⁹, and Ellen De Langhe⁵⁰, , Carlomaurizio Montecucco⁵¹, Petros Sfikakis⁵², Michele Iudici⁵³, Stefan Heitmann⁵⁴, Madelon Vonk⁵⁵, Anna-Maria Hoffmann-Vold⁵⁶, Oliver Distler⁵⁷, Marco Matucci-Cen⁵⁸, Cosimo Bruni⁵⁷, ¹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ²University of Florence, Florence, Florence, Italy, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, ⁴Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ⁵Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁶Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, ⁷Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ⁸Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ⁹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹⁰Hospital Universitario Vall d'Hebron Passeig, Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Barcelona, Spain, Zaragoza, Spain, ¹¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹²Charité University Hospital, Department of Rheumatology, Berlin, Germany, Berlin, Germany, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ¹⁴University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹⁵Leiden University Medical Center, Leiden, Netherlands, ¹⁶Kerckhoff-Klinik Bad Nauheim, Berlin, Germany, ¹⁷JLU Giessen, Campus Kerckhoff, Department of Rheumatology and Clinical Immunology Center, Bad Nauheim, Germany, Bad Nauheim, Germany, ¹⁸Rambam Health Care Campus, Rheumatology Institute, Haifa, Israel, israel, Israel, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ²¹Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, ²²University College London, UK, London, United Kingdom, ²³Sapienza University of Rome, Department of Translational and Precision Medicine Azienda Ospedaliero-Universitaria Policlinico Umberto ¹-Centro di riferimento regionale per la sclerosi sistemica, Rome, Italy, rome, Italy, ²⁴Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ²⁵Université Paris Cité, Paris, France, ²⁶University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²⁷Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, ²⁸Bordeaux University Hospital, Bordeaux, France, ²⁹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³⁰Poitiers University Hospital, Department of Internal Medicine, Poitiers, France, MIGNALOUX-BEAUVOIR, France, ³¹Rheumatology Unit, Department of Medicine and Public Health, AOU and University of Cagliari, Cagliari, Italy, ³²Waikato Hospital, Hamilton, New Zealand, ³³University of Leeds, Leeds, United Kingdom, ³⁴Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ³⁵University of Zagreb, School of Medicine, University Hospital Center Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, zagreb, Croatia, ³⁶University of Pécs, Department Of Rheumatology And Immunology, Medical Centre, Pecs, Hungary, Pecs, Hungary, ³⁷Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Rheumatology Department, Lisbon, Portugal, Paris, France, ³⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ³⁹University of Medicine and Pharmacy Iuliu Hatieganu Cluj, Clinica Reumatologie, Cluj-Napoca, Romania, Cluj-Napoca, Romania, ⁴⁰Stanford University, Stanford, CA, ⁴¹Fernando Fonseca Hospital, Department of Medicine IV, Systemic Immunomediated Diseases Unit, Amadora, Portugal, amadora, Portugal, ⁴²Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Rome, Italy, ⁴³University of Foggia, Department of Medical and Surgical Sciences, Rheumatology Unit, Foggia, Italy, foggia, Italy, ⁴⁴Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil, curitiba, Brazil, ⁴⁵Rutgers- RWJ Medical School, South Plainfield, NJ, ⁴⁶Meir Medical Center, Kfar-Saba, Israel, Kefar Sava, Israel, ⁴⁷Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁴⁸Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁴⁹UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁵⁰University Hospital Leuven, Laboratory of Tissue Homeostasis and Disease, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, ⁵¹Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy, ⁵²NKUA - SCHOOL OF MEDICIN, Athens, Greece, ⁵³Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ⁵⁴Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199 Stuttgart, Germany, ⁵⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵⁶Oslo University Hospital, Oslo, Norway, ⁵⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵⁸University San Raffaele Milano, Milano, Italy

Background/Purpose: Precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc) associates with severe morbidity and mortality. The prothrombotic state observed in idiopathic pulmonary arterial hypertension (PAH)…
Abstract Number: 0672 • ACR Convergence 2025
Determinants of Progressive Microstomia in Systemic Sclerosis: Insights from the GENISOS Cohort with a Focus on GI Involvement
Francesca Romana Di Ciommo¹, Ashish Balar², Robert M. Anderton², Michael Hughes³, Brian Skaug⁴, Maureen Mayes⁵, Shervin Assassi⁶, Ali Y Ayla² and Zsuzsanna McMahan⁷, ¹La Sapienza University of Rome, Rome, Italy, ²UTHealth Houston, Houston, TX, ³Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵UT Health Houston Division of Rheumatology, Houston, TX, ⁶Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁷UT Health Houston, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune condition characterized by vascular abnormalities, immune dysregulation, and progressive fibrosis affecting both the skin and internal organs.…
Abstract Number: 0808 • ACR Convergence 2025
Spatial Transcriptomics Show Fibroblast LIF Receptor Drives Fibrosis in Systemic Sclerosis
Mari Kamiya¹, Hung Nguyen¹, Miles Tran², Ce Gao³, Sergio Poli¹, Yunju Jeong⁴, Louis Merriam⁵, Jinjun Shi⁶, Rachel Knipe⁷, Katharine Black⁸, Lida Hariri⁹, Carol Feghali-Bostwick¹⁰, Rodney Infante¹¹, Janelle Pugashetti¹², Justin Oldham¹², Ilya Korsunsky¹³, Kevin Wei¹⁴ and Edy Kim¹, ¹Division of Pulmonary and Critical Care Medicine, Department of Medicine (DOM), Brigham and Women's Hospital (BWH); Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁴Division of Pulmonary and Critical Care Medicine, Department of Medicine (DOM), Brigham and Women's Hospital (BWH), Harvard Medical School, Boston, MA, United States; Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul, Republic of Korea, ⁵Division of Pulmonary and Critical Care Medicine, Department of Medicine (DOM), Brigham and Women's Hospital (BWH), Boston, MA, ⁶Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital (BWH); Harvard Medical School, Boston, MA, ⁷Division of Pulmonary and Critical Care Medicine, DOM, Massachusetts General Hospital; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital; Harvard Medical School, Boston, MA, ⁸Division of Pulmonary and Critical Care Medicine, DOM, Massachusetts General Hospital; Harvard Medical School, Boston, MA, ⁹Department of Pathology, Massachusetts General Hospital; Division of Pulmonary and Critical Care Medicine, DOM, Massachusetts General Hospital; Harvard Medical School, Boston, MA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Center for Human Nutrition, Dept. of Molecular Genetics, DOM, University of Texas Southwestern, Dallas, TX, ¹²Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, ¹³Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Division of Genetics, DOM, BWH; Harvard Medical School, Boston, MA, ¹⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune, fibroinflammatory disease of skin and visceral organs. Current SSc therapies have limited efficacy for progressive fibrosis. Our prior…
Abstract Number: 2555 • ACR Convergence 2025
Ergonomic Modifications: Findings From the Making it WorkTM Systemic Sclerosis Program
Janet Poole¹, Mary Thelander¹ and Kristine Carandang², ¹University of New Mexico, Albuquerque, NM, ²Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA
Background/Purpose: Work disability in people with systemic sclerosis (SS) increases substantially from diagnosis to three years after disease onset. Ergonomic modifications help people with physical,…
Abstract Number: 2482 • ACR Convergence 2025
Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
Francesco Bonomi¹, Cosimo Bruni², Silvia Laura Bosello³, Fabio Cacciapaglia⁴, Corrado Campochiaro⁵, Roberto Caporali⁶, Veronica Codullo⁷, Maria Antonietta D'Agostino⁸, Lorenzo Dagna⁹, Rossella De Angelis¹⁰, Giacomo de Luca¹¹, Dilia Giuggioli¹², Serena Guiducci¹³, Florenzo Iannone¹⁴, Francesca Ingegnoli¹⁵, Carlomaurizio Montecucco⁷, Valeria Riccieri¹⁶, Clodoveo Ferri¹⁷, Marco Matucci-Cerinic¹⁸ and Silvia Bellando Randone¹⁹, ¹University Hospital Careggi, Florence, Florence, Toscana, Italy, ²University of Zurich, Zurich, Switzerland, ³Division of Rheumatology and Clinical Immunology - Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy, ⁴Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, ⁵IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁷Policlinico San Matteo, Pavia, Pavia, Italy, ⁸Catholic University of the Sacred Heart, Rome, Rome, Italy, ⁹Ospedale San Raffaele, Milano, Italy, ¹⁰Polytechnic University of Marche, Ancona, Ancona, Italy, ¹¹Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, ¹²Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., Modena, Emilia-Romagna, Italy, ¹³Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Clinica Reumatologica, Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza ²⁰²³-²⁰²⁷, Università degli Studi di Milano, Milan, Italy, Milan, Italy, ¹⁶Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy, ¹⁷University of Modena and Reggio Emilia, Modena, Modena, Italy, ¹⁸University San Raffaele Milano, Milano, Milan, Italy, ¹⁹University of Florence, Florence, Italy
Background/Purpose: Gastrointestinal (GI) involvement affects over 80% of patients with systemic sclerosis (SSc), contributing significantly to morbidity and representing the third leading cause of disease-related…
Abstract Number: 1868 • ACR Convergence 2025
Global Downregulation of Fli1 in Mice Induces Cardiac Dysfunction via Enhanced β-fatty acid Oxidation and Collagen Deposition
Knowledge Mudhibadhi Moyo¹, Fatima-Ezzahrae El Adili², Maria Trojanowska¹ and Andreea Bujor¹, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Revere, MA
Background/Purpose: Primary cardiac involvement is a common complication of Systemic sclerosis (SSc), characterized by fibrosis and diastolic dysfunction, presumably due to microvascular dysfunction and repeated…
Abstract Number: 1581 • ACR Convergence 2025
The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
Marie-Elise Martel¹, Zélie Guitton², Aurélien Chepy¹, SEBASTIEN SANGES³, Eric Hachulla⁴, David Launay¹ and Vincent Sobanski⁵, ¹Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ - INFINITE - Institut de Recherche Translationnelle en Inflammation, Lille, France., Lille, France, ²CH Lens, Lens, France, ³Medecine Interne CHRU Lille, Lille, France, ⁴University of Lille, LILLE, France, ⁵Université de Lille, Lille, France
Background/Purpose: Calcinosis is a high-burden, key manifestation of systemic sclerosis (SSc), with a challenging therapeutic management. Yet, its precise prevalence and association with SSc charcateristics…
Abstract Number: 1537 • ACR Convergence 2025
Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Melanie Hagen¹, Fabian Müller², Andreas Wirsching¹, Soraya Kharboutli³, Silvia Spoerl³, Christina Duesing⁴, Tobias Krickau⁵, Markus Metzler⁵, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Ingrid Vasova³, Marc Saake⁵, Stefan Schliep⁵, Torsten Kubacki⁶, Nicolas Hunzelmann⁶, Laura Bucci¹, Jule Taubmann⁷, Christina Bergmann¹, Andrea-Hermina Györfi⁸, Sascha Dietrich⁹, Jörg Distler¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Klinik für Rheumatologie, Düsseldorf, Germany, ⁵Friedrich-Alexander-Universität Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶University and University Hospital Cologne, Cologne, Germany, Cologne, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁹Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Duesseldorf, Germany, ¹⁰University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment strategies for severe B-cell driven autoimmune diseases (AID) like Systemic Lupus erythematosus (SLE), Systemic…
Abstract Number: 0969 • ACR Convergence 2025
FOXO1 Mediated Polysialic Acid Dysregulation in Severe Systemic Sclerosis (SSc): A Novel Biomarker and Therapeutic Target?
Lamia Khan¹, Lisa Willis², Jan Storek³, Desiree Redmond⁴, Robert Gniadecki⁴ and Mohammed Osman¹, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Systemic sclerosis (SSc) is a life-threatening autoimmune disease where fibroblasts (FB) contribute to disease severity by resisting apoptosis and driving excessive skin fibrosis. Among…
Abstract Number: 0700 • ACR Convergence 2025
Distinct Breath Metabolomic Signature in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension
Martina Iacubino¹, Lorenzo Rocco², Marco Vicenzi², Chiara Bellocchi², Marta Mozzo³, adriana severino³, Monica Caronni³, Alessandro Santaniello³, Gaia montanelli³, Barbara Vigone³, LIam Grimmett⁴, Matt Kerr⁴ and Lorenzo Beretta⁵, ¹UNIMI, Milano, Milan, Italy, ²University of Milan, Milan, Italy, ³Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁴Owlstone Medical, Cambridge, United Kingdom, ⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Accurate and early diagnosis of SSc-PAH…
Abstract Number: 0673 • ACR Convergence 2025
Association Between Vasoactive-Vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence From a EUSTAR Study
Nicola Farina¹, Silvia Bellando-Randone², SEBASTIEN SANGES³, hilde Bjørkekjær⁴, lorenzo tofani⁵, Marie-Elise Truchetet⁶, Vanessa Smith⁷, Andra Balanescu⁸, Christina Bergmann⁹, Yannick Allanore¹⁰, Philipp Klemm¹¹, simona Truglia¹², Luca Idolazzi¹³, Christopher Denton¹⁴, Roberta Foti¹⁵, anna Wojteczek¹⁶, Emmanuel Chatelus¹⁷, Madelon Vonk¹⁸, Serena Guiducci¹⁹, David Launay²⁰, Eric Hachulla²¹, Jeska de Vries-Bouwstra²², Anna-Maria Hoffmann-Vold²³, Marco Matucci-Cerinic²⁴, Oliver Distler²⁵ and Cosimo Bruni²⁶, ¹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ²University of Florence, Florence, Florence, Italy, ³Medecine Interne CHRU Lille, Lille, France, ⁴Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, ⁵Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷Ghent University Hospital, Gent, Belgium, ⁸UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹⁰Université Paris Cité, Paris, France, ¹¹Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ¹²Reumatologia, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy, rome, Italy, ¹³Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, ¹⁴University College London, UK, London, United Kingdom, ¹⁵Division of Rheumatology, A.O.U. Policlinico-San Marco, Catania, Italy, Catania, Italy, ¹⁶Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdańsk, University Clinical Centre, Gdańsk, Poland, Gdańsk, Poland, ¹⁷Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹⁸Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ²⁰Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ²¹University of Lille, LILLE, France, ²²Leiden University Medical Center, Leiden, Netherlands, ²³Oslo University Hospital, Oslo, Norway, ²⁴University San Raffaele Milano, Milano, Milan, Italy, ²⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ²⁶University of Zurich, Zurich, Switzerland
Background/Purpose: Vasoactive-vasodilating drugs (VVD) are the cornerstone of the treatment of pulmonary arterial hypertension (PAH), a form of precapillary pulmonary hypertension (pPH) that represents a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].